Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized, placebo-controlled, double-masked proof-of-concept study of runcaciguat in NPDR
2020-002333-15Phase 2Terminated
- Sponsor
- Bayer
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in nonproliferative diabetic retinopathy (NPDR) comparing Runcaciguat with Placebo (2 arms). Primary endpoint: DRSS improvement. Started Sep 2020; status: terminated.
02
Drugs
runcaciguat
03
Conditions
nonproliferative diabetic retinopathy (NPDR)
Beyond the preview
Go deeper on 2020-002333-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002333-15.